Drug Profile
MDNA 55
Alternative Names: cpIL4-PE; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321Latest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA); Neurocrine Biosciences
- Developer Medicenna Therapeutics; Neurocrine Biosciences; Sophiris Bio
- Class Antineoplastics; Drug conjugates; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action Apoptosis stimulants; Immunostimulants; Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioblastoma
- Preclinical Brain cancer; Glioma
- Research Bladder cancer
- No development reported Brain metastases
- Discontinued Solid tumours